Oklahoma judge denies motion to end case against drugmaker

State's attorney Brad Beckworth speaks during oral arguments in Oklahoma's opioid trial Monday, July 8, 2019 in Norman, Okla. Attorneys for Johnson & Johnson were asking an Oklahoma judge to end the state's opioid public nuisance lawsuit against them, arguing state statutes and case law don't support it. Judge Thad Balkman ruled that Oklahoma's ongoing opioid drug lawsuit against Johnson & Johnson can move forward. Looking on at center is Larry Ottaway, one of the attorneys for Johnson & Johnson. (AP Photo/Sue Ogrocki)
Oklahoma Attorney General Mike Hunter listens during oral arguments in the state's opioid trial Monday, July 8, 2019 in Norman, Okla. Attorneys for Johnson & Johnson were asking an Oklahoma judge to end the state's opioid public nuisance lawsuit against them, arguing state statutes and case law don't support it. Judge Thad Balkman ruled that Oklahoma's ongoing opioid drug lawsuit against Johnson & Johnson can move forward. (AP Photo/Sue Ogrocki)
Larry Ottaway, one of the attorneys for Johnson & Johnson, listens during oral arguments in Oklahoma's opioid trial Monday, July 8, 2019 in Norman, Okla. Attorneys for Johnson & Johnson were asking an Oklahoma judge to end the state's opioid public nuisance lawsuit against them, arguing state statutes and case law don't support it. Judge Thad Balkman ruled that Oklahoma's ongoing opioid drug lawsuit against Johnson & Johnson can move forward. (AP Photo/Sue Ogrocki)
Judge Thad Balkman rules that Oklahoma's ongoing opioid drug lawsuit against Johnson & Johnson can move forward, Monday, July 8, 2019 in Norman, Okla. Attorneys for Johnson & Johnson had asked Balkman to end the Oklahoma's opioid public nuisance lawsuit against them, arguing state statutes and case law don't support it. (AP Photo/Sue Ogrocki)
State's attorney Brad Beckworth speaks during oral arguments in Oklahoma's opioid trial Monday, July 8, 2019 in Norman, Okla. Attorneys for Johnson & Johnson were asking an Oklahoma judge to end the state's opioid public nuisance lawsuit against them, arguing state statutes and case law don't support it. Judge Thad Balkman ruled that Oklahoma's ongoing opioid drug lawsuit against Johnson & Johnson can move forward. (AP Photo/Sue Ogrocki)

OKLAHOMA CITY — An Oklahoma judge decided Monday the state's ongoing opioid drug lawsuit against consumer products giant Johnson & Johnson can move forward, rejecting the company's argument that the state failed to prove its public-nuisance claim.

District Judge Thad Balkman denied Johnson & Johnson lawyers' motion asking him to end the case mid-trial and rule in favor of the New Brunswick, New Jersey-based company and its subsidiaries, including Janssen Pharmaceuticals Inc. The defendants filed the motion last week after the state rested its case. The trial began May 28.

Company attorneys had argued the state's case is an inappropriate use of a public-nuisance claim , typically reserved for disputes over property such as an unruly saloon or a smelly livestock operation that bothers neighbors.

"There is no support in Oklahoma law for the state's public-nuisance theory," Johnson & Johnson attorney Steve Brody said in court, likening the state's case to forcing fast-food restaurants to pay for anti-obesity programs.

Oklahoma argues the company helped fuel the state's opioid crisis with an aggressive marketing campaign that overstated the drug's effectiveness and understated the addiction risk. The state has proposed a $17.5 billion abatement plan to address the problem over the next 30 years, a figure that attorneys for Johnson & Johnson say is wildly inflated.

"We don't have to show they're the cause. We have to show they're a cause. And we did it," said Brad Beckworth, an attorney for Oklahoma.

Before the start of the trial, Oklahoma reached a $270 million settlement with Oxycontin-maker Purdue Pharma and an $85 million deal with Israeli-owned Teva Pharmaceutical Industries Ltd.

Oklahoma Attorney General Mike Hunter described the judge's ruling Monday as a victory for the state and for victims of the opioid epidemic.

"The motion, filed by the company last week, was the latest attempt to cut and run from the crisis it created," Hunter said in a statement. "Our case has revealed how corporate greed got in the way of responsible practices by Johnson & Johnson and its subsidiaries."

John Sparks, a local attorney for Johnson & Johnson, said the company recognizes the toll the opioid crisis has taken on states across the country and is committed to working on measures to address it. But, Sparks added, it's unrealistic to have a single company pay for huge government programs to abate the crisis.

"We will continue to present our case and believe the evidence shows Janssen did everything a responsible manufacturer of prescription opioid medicines should do," Sparks said in a statement. "The state's over-reaching interpretation of the statute is unsustainable and will force the state into uncharted legal waters long after this case is decided."

___

Follow Sean Murphy at www.twitter.com/apseanmurphy

You may also interested in

Self-driving cars go public; Uber offers rides in Pittsburgh

Aug 18, 2016

The option to hail a ride in a self-driving car will soon be available to Uber users in Pittsburgh

Republicans to query firms that ran Clinton's private server

Aug 23, 2016

Republicans are stepping up attacks on former Secretary of State Hillary Clinton's use of private email, alleging that foreign donors to the Democratic presidential nominee's family charity got preferential treatment from her department

Delphi, Mobileye join forces on autonomous car platform

Aug 23, 2016

Auto parts and electronics company Delphi Automotive is joining with Israeli software maker Mobileye to develoDelphi and Mobileye plan to build a complete autonomous driving platformp the building blocks for a fully autonomous car in about two years

People also read these

Valeant, attempting to normalize operations, names new CFO

Aug 22, 2016

Valeant Pharmaceuticals is replacing Robert Rosiello as chief financial officer as the embattled pharmaceutical company attempts to normalize operations amid a host of ongoing investigations and class action suits

Delphi, Mobileye join forces on autonomous car platform

Aug 23, 2016

Auto parts and electronics company Delphi Automotive is joining with Israeli software maker Mobileye to develoDelphi and Mobileye plan to build a complete autonomous driving platformp the building blocks for a fully autonomous car in about two years

How EpiPen's maker raised prices, and hackles, so much

Aug 23, 2016

Sky-high price hikes for an emergency allergy medicine are making drugmaker Mylan the latest target for patients and politicians infuriated by soaring drug costs

Emporium Post fulfils the need to know all things about consumers and how businesses can take this opportunity to reach their own customers.

Contact us: sales@emporiumpost.com

Join our mailing list now!